Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study

• Published in: Arthritis research & therapy Vol. 25; no. 1; pp. 1 - 13
• Main Authors: Hamberg, Viggo, Sohrabian, Azita, Volkmann, Elizabeth R., Wildt, Marie, Löfdahl, Anna, Wuttge, Dirk M., Hesselstrand, Roger, Dellgren, Göran, Westergren-Thorsson, Gunilla, Rönnelid, Johan, Andréasson, Kristofer
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 04.09.2023; BioMed Central; BMC
• Subjects: Analysis; Antibodies; Antigens; Arthritis; Autoantibodies; Autoantibody; Autoimmune diseases; Autoimmunitet och inflammation; Autoimmunity and Inflammation; Biomarker; Blood & organ donations; Bronchoscopy; Care and treatment; Clinical Medicine; Development and progression; Humans; Immunoassay; Immunohistochemistry; Immunology; Interstitial lung disease; Kinases; Klinisk medicin; Lavage; Lung diseases; Lung Diseases, Interstitial; Lungs; Medical and Health Sciences; Medicin och hälsovetenskap; Mortality; Patients; Pulmonary Fibrosis; Pulmonary function tests; Rheumatology; RNA polymerase; Ro52; Scleroderma; Scleroderma (Disease); Scleroderma, Diffuse; Scleroderma, Systemic/complications; Systemic scleroderma; Systemic sclerosis; Testing; United Kingdom; United States > US

Background Interstitial lung disease (ILD) is the most common cause of death in patients with systemic sclerosis (SSc). Prognostic biomarkers are needed to identify SSc-ILD patients at risk for progressive pulmonary fibrosis. This study investigates autoantibodies measured in bronchoalveolar lavage...